Trial reportLipids in health and disease2025
Culturally adapted hypocaloric diet improves hepatic steatosis, inflammatory and oxidative biomarkers in Egyptian MASLD patients: a single-arm interventional study.
Trial report in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effect of nutritional intervention on interleukin-18 and alpha-2-macroglobulin in women with obesity and metabolic dysfunction-associated fatty liver disease: a prospective cohort study.Journal of health, population, and nutrition · 2026Article
- Systemic hematologic, metabolic, and inflammatory dysregulation in liver cirrhosis and hepatocellular carcinoma: diagnostic utility of novel indices in an Egyptian cohort.BMC gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) represents a growing public health challenge in Egypt, driven by westernized dietary patterns, urbanization, and physical inactivity. Despite lifestyle intervention being the first-line management, data on structured hypocaloric diets tailored to Egyptian patients remain limited, particularly regarding their effects on hepatic steatosis, inflammatory pathways, and oxidative stress biomarkers. This study aimed to evaluate the impact of a culturally adapted 6-month hypocaloric diet on hepatic fat reduction, metabolic parameters, inflammatory-oxidative biomarkers, and lifestyle factors in Egyptian MASLD patients, with additional exploration of weight-independent mechanisms.
methodsIn this single-center interventional trial, 30 newly diagnosed MASLD patients received a personalized hypocaloric diet (500-1000 kcal/day deficit). Outcomes measured at baseline and post-intervention included anthropometrics, liver enzymes, metabolic profile, hepatic steatosis (CAP score), inflammatory markers (TNF-α, MDA), antioxidant enzymes (SOD, CAT), and lifestyle behaviors (physical activity, sleep). Advanced statistical analyses included effect size estimation, multivariate regression, mediation analysis, and subgroup comparisons (lean vs. obese MASLD).
resultsAfter 6 months, patients achieved significant reductions in weight (- 10.9 kg), BMI (- 3.9 kg/m
conclusionA culturally tailored hypocaloric diet effectively improved hepatic steatosis, inflammatory status, and antioxidant capacity in Egyptian MASLD patients. These improvements were partially weight-independent and partially mediated by anti-inflammatory responses. These findings support hypocaloric dietary strategies as a potentially scalable therapeutic option for MASLD management in resource-limited settings, though the absence of a control group limits causal inference, and further evaluation of implementation feasibility and cost-effectiveness is warranted. Additional benefits were also observed in lifestyle behaviors such as physical activity and sleep.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.